Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.06. | Immunome Inc. - 8-K, Current Report | 1 | SEC Filings | ||
19.05. | Immunome stock rating cut to Hold by Boral Capital | 2 | Investing.com | ||
12.05. | Immunome GAAP EPS of -$0.52 beats by $0.14, revenue of $2.93M beats by $2.47M | 1 | Seeking Alpha | ||
12.05. | Immunome Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.05. | Immunome Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.03. | Hedge Fund and Insider Trading News: Michael Hintze, Stanley Druckenmiller, Bill Ackman, Eisler Capital, Immunome Inc (IMNM), and More | 3 | Insider Monkey | ||
26.03. | Immunome stock rises after insider purchase | 1 | Seeking Alpha | ||
20.03. | Immunome stock target cut to $25 by Guggenheim | 1 | Investing.com | ||
IMMUNOME Aktie jetzt für 0€ handeln | |||||
19.03. | Immunome Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
19.03. | Immunome GAAP EPS of -$5.00 misses by $0.62, revenue of $9.04M misses by $0.37M | 1 | Seeking Alpha | ||
19.03. | Immunome Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
19.03. | Immunome Inc. - 8-K, Current Report | 2 | SEC Filings | ||
30.01. | Immunome Inc. - 8-K, Current Report | - | SEC Filings | ||
30.01. | Immunome-Aktie stürzt nach Preisfestsetzung für öffentliches Angebot ab | 4 | Investing.com Deutsch | ||
30.01. | Immunome stock tumbles after public offering pricing | 1 | Investing.com | ||
29.01. | Immunome plans to commence underwritten public offering | 4 | Seeking Alpha | ||
29.01. | Immunome kündigt Aktienemission im Wert von 125 Millionen US-Dollar an | 2 | Investing.com Deutsch | ||
29.01. | Immunome announces $125 million stock offering | 4 | Investing.com | ||
23.01. | Immunome Inc. - 8-K, Current Report | - | SEC Filings | ||
13.11.24 | Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update | 173 | Business Wire | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 29,410 | +0,93 % | Der Anteilsschein von Moderna läuft prima: Große Kursgewinne! (27,015 €) | Die Aktie von Moderna zählt heute zu den großen Gewinnern an der Börse. Der Titel verteuert sich am Dienstag deutlich. Zu den auffälligsten Papieren an der US-amerikanischen Börse gehört heute die Aktie... ► Artikel lesen | |
CRISPR THERAPEUTICS | 50,50 | 0,00 % | Cathie Wood's ARK buys CRSP stock, sells ROKU and MASS | ||
TEMPUS AI | 51,00 | +0,08 % | Cathie Wood's ARK buys Tempus AI stock, sells Block and Roku | ||
OCULAR THERAPEUTIX | 9,308 | -1,71 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
CORCEPT THERAPEUTICS | 62,04 | +0,65 % | Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial | ||
MACROGENICS | 1,341 | -3,25 % | MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results | First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination... ► Artikel lesen | |
ULTRAGENYX | 26,600 | 0,00 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis | NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled... ► Artikel lesen | |
AMNEAL PHARMACEUTICALS | 6,950 | 0,00 % | Amneal Pharmaceuticals LLC: Amneal to Report Second Quarter 2025 Results on August 5, 2025 | ||
4D MOLECULAR THERAPEUTICS | 4,380 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution | 4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 20274FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns... ► Artikel lesen | |
PROKIDNEY | 5,210 | 0,00 % | Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,715 | 0,00 % | Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia | Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition... ► Artikel lesen | |
BEAM THERAPEUTICS | 22,000 | 0,00 % | H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT | ||
COGENT BIOSCIENCES | 10,840 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
NURIX THERAPEUTICS | 12,680 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 25,890 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen |